Surgery with adjuvant endocrine therapy alone can be sufficient for certain early-stage cancers, but locally advanced or higher risk cancers may also require chemotherapy, biologic human epidermal growth factor receptor 2 (Her2)-targeted therapy, radiation to the chest wall or axillary nodes, and/or ovarian suppression [10, 14, 15]. The gene discussed is ERBB2; the disease is cancer.